18F GP1

Drug Profile

18F GP1

Alternative Names: 18F-GPI; 18F-GP1; F18-GP1; GP1-18F; GP1-F18

Latest Information Update: 16 Jul 2015

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Piramal Imaging
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 14 Nov 2014 18F GP1 is available for licensing as of 14 Nov 2014. http://www.piramal.com/imaging/about-us/business-dev-licensing.html
  • 01 Jan 2014 Pharmacodynamics data from a preclinical trial in Thrombosis released by Piramal
  • 30 Dec 2013 Preclinical trials in Thrombosis (Diagnosis) in Germany before November 2014 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top